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Isoniazid preventive therapy (IPT) is a key strategy recommended 
by the World Health Organization (WHO) for the prevention 
of tuberculosis (TB) in patients infected with HIV. The WHO 
recently updated its guidelines and now recommends IPT for a 
duration of at least 36 months for adults and adolescents living 
with HIV in resource-limited settings.[1] The WHO notes that the 
implementation of continuous IPT requires considerations of: (i) TB 
epidemiology; (ii) health infrastructure; (iii) programmatic priorities; 
and (iv) patient adherence. Individuals with HIV are at an increased 
risk of developing active TB infection, with studies[2] showing that the 
incidence of TB doubles within the first year of HIV seroconversion 
and increases fourfold after 2 years. This article discusses some of the 
challenges Namibia currently faces in its ongoing fight against TB and 
the implications of the new WHO IPT recommendations.
Discussion
Namibia, an upper-middle-income sub-Saharan African country, 
continues to grapple with what are among the highest prevalences of 
both HIV and TB worldwide. This, coupled with a sparsely distributed 
population, presents a great challenge in terms of healthcare delivery.
The incidence of TB in Namibia remains one of the highest in the 
world, with a case notification rate of 589 cases per 100 000 population. [3] 
In its continued effort to attain its vision of a Namibia where TB is no 
longer a health threat,[4] the Ministry of Health and Social Services 
(MoHSS) works very closely with both primary healthcare providers and 
public health services at national, regional and district levels to ensure 
the success of the WHO directly observed therapy, short-course (DOTS) 
strategy in the treatment of TB patients, and to create public awareness 
of practical interventions for the prevention of TB, especially in people 
living with HIV. According to the 2012/2013[5] MoHSS report, the TB 
and HIV co-infection rate at the time stood at 47%.
A 2014 - 2015 MoHSS report[6] indicates that there has been a small 
decline in case numbers of TB, suggesting a declining incidence of the 
disease burden in the country. Significant improvements in TB/HIV 
service coverage are exemplified by: (i) improved HIV testing for 
TB patients, currently at 92% compared with 76% in 2010; and (ii) 
improved coverage of antiretroviral therapy (ART) among TB/HIV 
patients, up to 84% from 43% in 2010.
The overall prevalence of HIV in the country is currently estimated 
at 13.1% in the general population although there is wide variation 
in different regions. Despite government efforts to improve ART 
coverage, Namibia remains one of the top ten countries in the world 
worst affected by HIV, which in turn continues to fuel the rise of TB 
in the country. Over 230 000 people aged >15 years are living with 
HIV.[7] The number of people living with HIV is expected to increase 
as ART coverage increases, reducing the numbers of AIDS-related 
deaths.
Health infrastructure and cost implications
The structure of the health sector in Namibia aims to decentralise 
health services as much as possible while integrating public health 
strategies in service delivery. The continued collaboration of the 
Namibia TB Leprosy Program with the National Institute of Pathology 
and the Division of Pharmaceutical Services has demonstrated 
outstanding success in ensuring the timely provision of quality 
laboratory services, as well as uninterrupted supply of TB drugs to 
the TB treatment centres in both the capital city and remote clinics 
in the rural areas.
However, in health facilities in the peripheral regions, including 
the border towns, services are still grossly inadequate, especially in 
terms of human resources. Studies[8] in the Omaheke region show 
that more service-related factors than community-related factors 
influenced the successful implementation of community-based TB 
care. According to the MoHSS,[6] the TB delivery programme in this 
region was inadequate, with a 51.4% defaulter rate.
In its health budget planning, the government of Namibia needs 
to consider the projected cost implications of adopting the new 
36-month IPT strategy as opposed to a 6-month IPT strategy. Smith 
et al.[9] examined the cost of implementation of IPT in Botswana, 
where ART is readily available, and found that a 36-month IPT 
strategy for HIV-positive individuals was more cost-effective for 
reducing both TB and death than individual costs of: (i) providing 
IPT without tuberculin skin testing (TST); (ii) providing only 
6  months of IPT; or (iii) expanding ART eligibility without IPT. 
Gupta et al.[10] also showed that models providing ART coverage to 
90%, TB infection control and 36-month IPT strategy averted most 
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TB cases and were more cost-effective than models that provided less 
ART coverage.
Possible adverse events and the balance between  
benefit and harm
The key outcome of interest in the development of the new 
recommendations was progression to active TB. Other outcomes of 
interest include adverse effects and adherence. In the formulation 
of the new guidelines, a meta-analysis of adverse events was not 
performed because of the heterogeneity of the definition of side-
effects by the different studies that were considered by the WHO. 
The study by Swaminathan et al.[11] did not report information on 
adherence, while Martinson et al.’s[12] recorded adherence of 60.4% 
in the 36-month IPT group compared with 83.8% in the 6-month 
IPT group. There is also currently insufficient evidence to indicate 
whether continuous IPT use increases the risk of development 
of isoniazid resistance. According to Swaminathan et al.[11] and 
Samandari et al.,[13] the observed proportion of resistance cases 
among TB cases was similar to the expected rate. However, resistance 
patterns are known to vary vastly from region to region.
Conclusion
Implementation of the new IPT strategy in HIV-positive patients 
would be likely to record success alongside ART strategies, as patients 
can be counselled for drug adherence and monitored on therapy at 
the same time. However, this will require a renewed commitment 
from the government of Namibia and its collaborators to implement 
the intervention, finance the additional costs associated with drug 
supply and increase the human resources capacity.
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